DHCPL
Communicating safety information to patients and healthcare professionals is a public health responsibility, and is essential in promoting the safe and rational use of medicines, and preventing harm from adverse reactions.
This webpage serves to provide the public and healthcare professionals with easy access to important drug safety information, as approved by SAHPRA. Safety alerts provide important information and recommendations about therapeutic products; however, it does not necessarily imply that a product is considered unsafe.
Abic Vincristine 1 mg/ml; 2 mg/2 ml
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
Abitrexate 2,5 mg; 5 g/50 ml; 50 mg/2 ml; 500 mg/20 ml; 1000 mg/10 ml
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
Bupyra XL 150/300
This relates to the risk of Brugada syndrome associated with the use of bupropion-containing medicines.
View PDFCarbosin 150 mg/15 ml; 450 mg/45 ml; 600 mg/60 ml
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
Ciprol 250/500
Fluoroquinolone antibiotics: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones.
View PDFDasatinib Teva 20/50/70/100
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
Docetaxel Teva 20 mg; 80 mg
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
Doxorubicin-Sol PCH 10 mg/50 mg
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
Eposin 100 mg/5 ml
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
Fluracedyl 250/500/1000/5000
Fluoropyrimidine containing medicines and related substances: increased drug exposure and toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.
View PDFRecommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
View PDFLokit
Increased risk of subclinical acute interstitial nephritis associated with the use of proton pump inhibitors (PPIs) leading to acute kidney injury and/or chronic renal failure.
View PDFNurika 25/50/75/150; Pregabalin Ivax 25/50/75/150
This relates to the risk of serious breathing difficulty associated with the use of gabapentinoids (gabapentin and pregabalin).
View PDFOxaliplatin PCH 50 mg/10 ml; 100 mg/20 ml
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
View PDFPCH-Paclitaxel 30 mg; 100 mg; 300 mg
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
View PDFTamoplex 20 mg
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
View PDFTeva Carbilevo 25/100; 25/250
Dopaminergic medicines used in the treatment of Parkinson’s Disease: risk of dopamine dysregulation syndrome (DDS).
View PDFTeva Fludarabine 50 mg/2ml
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
View PDFVinblastine Teva 10
Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.
View PDF